25 studies recruiting now13 research sites across CanadaJoin the community
Human papillomavirus, or HPV, is a group of very common viruses passed on by skin-to-skin sexual contact. Most infections cause no symptoms and clear within about two years. A few persist, and those can lead to cancer years later.
HPV is not rare, and it is not a mark against anyone. The Canadian Immunization Guide estimates 75% of sexually active Canadians would have an HPV infection at some point if not immunised, making it the most common sexually transmitted infection in Canada.
It is also not fast-moving. The Public Health Agency of Canada notes that where a high-risk type persists, progression to invasive cancer usually takes 15 to 20 years or longer. That gap is what lets cervical screening find changes well before cancer develops.
Because HPV is usually silent, screening matters more than waiting for symptoms.
Some risk factors cannot be changed:
Others can often be worked on, usually with support from a health care team:
HPV itself is not routinely tested for outside cervical screening. Screening uses either an HPV test for high-risk types or a Pap test for cell changes, depending on your province or territory. An abnormal result leads to a repeat test or a colposcopy, where the cervix is examined closely and a tissue sample may be taken. Warts are diagnosed by how they look. There is no routine screening in Canada for HPV-related cancers of the throat, anus, penis, vagina or vulva.
Nothing treats the virus itself, so care targets what HPV causes. A health care team may discuss:
What suits one person will not suit another. These are decisions for you and your own clinician.
Canadian HPV research is now mostly about delivery and about the cancers screening does not cover. How long single-dose protection lasts is still being followed. Coverage is the other problem: the Canadian Partnership Against Cancer reports about 84% coverage for at least one dose among 14-year-olds in 2021 against a 90% target, varying widely between provinces. The Canadian Cancer Society reported in November 2025 that progress toward eliminating cervical cancer in Canada has stalled. Research areas include self-collection for screening, therapeutic vaccines, and whether screening is feasible for throat and anal cancers.
Taking part is voluntary. You give informed consent first, and you can stop at any time without affecting the care you get from your own doctor. No one can say in advance whether a study will help you personally.
This page is written in plain language for people considering clinical research. It is general health information, not medical advice, and it does not replace a conversation with your own doctor or nurse practitioner.
In its statement of July 2024, the National Advisory Committee on Immunization continued to strongly recommend HPV vaccination for everyone aged 9 to 26, and recommended using the nonavalent vaccine because it covers the greatest number of HPV types. It described one dose for people aged 9 to 20, with a two-dose schedule as an individual option, two doses for people aged 21 to 26, and two doses through shared decision-making with a health care provider for people 27 and older. A three-dose schedule continues to be recommended for people who are immunocompromised or living with HIV. NACI advises, but each province and territory decides what its programme funds and for whom, and those rules change.
Publicly funded school-based programmes exist in every province and territory, delivered in grades 4 to 7 according to the Canadian Partnership Against Cancer, and they cover all genders. Beyond the school programme it varies: some provinces run catch-up programmes, and Manitoba, Prince Edward Island and Newfoundland and Labrador have once-eligible-always-eligible policies. The Canadian Cancer Society notes that vaccination is recommended for people aged 9 to 45, but a recommendation and public funding are not the same thing. Check the immunisation page for your province or territory, or ask a pharmacist.
Almost certainly not. The Public Health Agency of Canada notes that most HPV infections clear on their own within about two years without treatment. Where a high-risk type does persist, progression to invasive cancer typically takes 15 to 20 years or longer, which is what makes cervical screening effective at finding changes long before cancer develops. HPV is common enough that the Canadian Immunization Guide estimates three quarters of sexually active Canadians would have it at some point without immunisation, while cervical cancer is estimated to affect 1,700 people in Canada in 2026.
Connecting Canadians with clinical research studies conducted by a network of physicians committed to advancing medicine — since 1995.
JoinAStudy.ca provides information about clinical research and does not provide medical advice, diagnosis, or treatment. Only a qualified study doctor can determine your eligibility for a study. Participation is always voluntary.
© 2026 JoinAStudy.ca · A network of Canadian physicians.|Designed by Pixelore.ca
